Table 1. Baseline characteristics of MM patients.
| Items | MM patients (N=92) |
|---|---|
| Age (years), mean ± SD | 56.7±8.3 |
| Gender, No. (%) | |
| Male | 59 (64.1) |
| Female | 33 (35.9) |
| Immunophenotype, No. (%) | |
| IgG | 51 (55.4) |
| IgA | 21 (22.8) |
| IgM | 1 (1.1) |
| IgD | 1 (1.1) |
| Bence-Jones protein | 18 (19.6) |
| Bone lesion, No. (%) | 68 (73.9) |
| Biochemical indexes | |
| Hb (g/dL), mean ± SD | 10.0±2.4 |
| Calcium (mg/dL), mean ± SD | 10.0±1.8 |
| Scr (mg/dL), mean ± SD | 1.6±0.5 |
| Albumin (mg/dL), mean ± SD | 3.9±0.7 |
| β2-MG (mg/L), median (IQR) | 4.4 (2.4–7.4) |
| LDH (U/L), median (IQR) | 194.9 (170.9–229.5) |
| Durie-Salmon stage, No. (%) | |
| II | 12 (13.0) |
| III | 80 (87.0) |
| ISS stage, No. (%) | |
| I | 23 (25.0) |
| II | 32 (34.8) |
| III | 37 (40.2) |
| Cytogenetics, No. (%) | |
| t(4;14) | 10 (10.9) |
| t(14;16) | 14 (15.2) |
| Del (17p) | 9 (9.8) |
MM, multiple myeloma; SD, standard deviation; Ig, immunoglobulin; Hb, hemoglobin; Scr, serum creatinine; β2-MG, β2-microglobulin; IQR, interquartile range; LDH, lactate dehydrogenase; ISS, international staging system.